代谢物在静脉血栓栓塞症发病机制中作用的因果探索:全代谢组孟德尔随机化研究
该研究以690种血浆代谢物和211种尿液代谢物为暴露,采用全代谢组孟德尔随机化与共定位分析评估其对静脉血栓栓塞症(VTE)的因果作用。经Bonferroni校正后,51种血浆代谢物和18种尿液代谢物与VTE风险显著相关,共定位证据支持37种代谢物的因果关系;中介分析显示8种代谢物介导6种可改变危险因素对VTE的影响。
要点
- 51种血浆代谢物和18种尿液代谢物经Bonferroni校正后与VTE风险显著相关。
- 共定位证据支持37种代谢物与VTE存在因果关系。
- 8种代谢物介导6种可改变危险因素对VTE的影响。
核心结论
- 本研究识别了与VTE风险相关的潜在代谢物生物标志物,并揭示了可改变危险因素与VTE之间的代谢中介物,为未来预防和治疗策略提供了新见解。
研究设计与样本
- 以690种血浆代谢物和211种尿液代谢物的遗传关联作为暴露,VTE结局来自大规模全基因组关联研究荟萃分析。
- 采用全代谢组孟德尔随机化与共定位分析评估代谢物对VTE的因果作用,使用MetOrigin进行代谢通路分析,并进行可成药性评估以优先筛选潜在治疗靶点。
- 采用两步孟德尔随机化框架阐明代谢物在可改变危险因素与VTE关系中的中介效应。
主要发现
- 经Bonferroni校正后,51种血浆代谢物和18种尿液代谢物与VTE风险显著相关。
- 共定位证据支持37种代谢物与VTE存在因果关系。
- 识别出11条与VTE相关代谢物有关的代谢通路,6种代谢物被优先列为潜在治疗靶点。
- 24种可改变危险因素与28种VTE相关代谢物相关,其中7种代谢物与VTE风险相关。
- 中介分析显示8种代谢物对6种可改变因素影响VTE具有显著中介效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is a significant global health burden, and metabolic alterations play a key role in its pathogenesis. However, previous studies have been constrained by several limitations, hindering clarification of the causal role of metabolites. OBJECTIVES: To comprehensively evaluate the causal roles of metabolites in the pathogenesis of VTE and determine whether metabolites mediate the relationships between modifiable risk factors and VTE. METHODS: Genetic associations involving 690 plasmas and 211 urinary metabolites were analyzed as exposures, while the outcomes for VTE were derived from a large-scale meta-analysis of genome-wide association studies. Metabolome-wide Mendelian randomization and colocalization analyses were performed to assess the causal role of metabolites in VTE. Metabolic pathway analysis was performed using MetOrigin, and druggability assessments were conducted to prioritize potential therapeutic targets. Additionally, a 2-step Mendelian randomization framework was employed to elucidate the mediating effects of metabolites on the relationships between modifiable risk factors and VTE. RESULTS: After Bonferroni correction, 51 plasma metabolites and 18 urinary metabolites were significantly associated with VTE risk. Colocalization evidence supported causal relationships for 37 metabolites with VTE. Eleven metabolic pathways were identified for VTE-related metabolites, and 6 metabolites were prioritized as potential therapeutic targets. Twenty-four modifiable risk factors were associated with 28 VTE-related metabolites, 7 of which were linked to VTE risk. Mediation analyses further revealed significant mediating effect of 8 metabolites on how 6 modifiable factors influenced VTE. CONCLUSION: This study identifies potential metabolite biomarkers associated with VTE risk and uncovered the metabolic mediators between modifiable risk factors and VTE, offering new insights for future prevention and treatment strategies.
引用
- Hu W, Bei Y, Chen G, et al. Causal insights into the role of metabolites in venous thromboembolism pathogenesis: a metabolome-wide Mendelian randomization study. J Thromb Haemost. 2025. PMID: 40157505. doi:10.1016/j.jtha.2025.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。